Drug Safety Issues Require “Courage” From Advisory Cmtes, Nissen Says
Executive Summary
Advisory committees should be strengthened to better scrutinize safety data and improve advice given to FDA, Steve Nissen (Cleveland Clinic Foundation) said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System
You may also be interested in...
Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb
The prominent concerns over FDA's drug safety oversight may be impacting advisory committees more than the agency itself, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested
Advisory Panels, Not FDA, Are Most Affected By Rx Safety Concerns – Gottlieb
The prominent concerns over FDA's drug safety oversight may be impacting advisory committees more than the agency itself, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb suggested
AstraZeneca Expands Pipeline With “Reduced Risk” Phase III Program
AstraZeneca is entering 2006 with an expanded, lower risk Phase III pipeline that concentrates on familiar therapeutic categories
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: